Le Lézard
Classified in: Health, Science and technology
Subject: LAW

Zimmer Biomet Announces Filing of Form 10 Registration Statement in Connection with Planned Spinoff of ZimVie; ZimVie to Host Investor Day on February 7

WARSAW, Ind. and WESTMINSTER, Colo., Jan. 21, 2022 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced that it has filed a Form 10 registration statement with the United States Securities and Exchange Commission ("SEC") in connection with the intended spinoff of its Dental and Spine businesses into a standalone, publicly traded company, ZimVie.

The Form 10 includes detailed information about ZimVie, such as historic financial information, a description of ZimVie's business and strategy, and other legal and financial disclosures. A copy of the Form 10 is available on the SEC website at www.sec.gov.

In addition, ZimVie will host a virtual Investor Day on Monday, February 7, 2022 from 11:00 a.m. to approximately 3:00 p.m. Eastern Time. The virtual event will feature presentations from ZimVie leaders outlining its Dental and Spine offerings, addressable market opportunity, financial outlook, business strategy, and the broader organizations supporting these businesses. The event will feature a live Q&A panel following speaker presentations.

A live and archived webcast of the event can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com

Zimmer Biomet announced in February 2021 its intent to form a new independent, publicly traded company to optimize resource allocation and drive toward market leadership. That transaction process remains on track, with an expected close in the first quarter of 2022.

About Zimmer Biomet 
Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence.  

With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation. 

For more information about our product portfolio, our operations in 25+ countries and sales in 100+ countries or about joining our team, visit www.zimmerbiomet.com or follow Zimmer Biomet on Twitter at www.twitter.com/zimmerbiomet.

About ZimVie
ZimVie will focus on the dental and spine markets and their respective growth drivers such as implants, surgical tools, bone graft substitutes, spinal fusion implants, non-fusion alternatives, and digital care management solutions. "Zim" derives from Zimmer Biomet, the new company's roots ? and "Vie" is the French word for "life," symbolizing the future. ZimVie's headquarters will be in Westminster, Colorado.

345 E. Main St. 
Warsaw, IN 46580 

Zimmer Biomet Media
Meredith Weissman
[email protected]

Zimmer Biomet Investors
Keri Mattox
[email protected]

Ezgi Yagci
[email protected]

ZimVie Investors 
Lynn Lewis or Marissa Bych
Gilmartin Group LLC
[email protected]
[email protected]

SOURCE Zimmer Biomet Holdings, Inc.

These press releases may also interest you

at 04:30
The "Cell Based Assay & High Content Screening Markets 2022 to 2026: Forecasts by User and Product. With Executive and Consultant Guides. including Customized Forecasting and Analysis. " report has been added to ResearchAndMarkets.com's offering....

at 04:08
China Ping An Insurance Overseas (Holdings) Limited, the main offshore investment and asset management platform of Ping An Insurance (Group) Company of China, Ltd. (2318.HK, 601318.SH), together with its subsidiaries ("PAOH"), is pleased to announce...

at 04:05
Medidata, a Dassault Systèmes company, will gather industry experts across drug development, clinical research and operations, data management and digital health to address the industry's most pressing challenges at NEXT London on May 24, 2022, at...

at 04:05
Over the last few years and during the global pandemic, the demand for wearables and longwear applications in the medical industry has significantly increased. For example, in diagnostics, monitoring and consumer health, the need for reliable bonding...

at 04:00
DelSiTech Ltd, the leading silica drug delivery technology company, based in Finland and Anticancer Bioscience Ltd., an innovative China-base and international company pioneers in synthetic lethal approaches to precision oncology, today announced a...

at 03:30
The global scanning electrochemical microscopy (SECM) market size is expected to grow by USD 41.90 million from 2019 to 2024 at a CAGR of 7% as per the latest market report by Technavio. 37% of the market's growth will originate from North America...

News published on 21 january 2022 at 09:07 and distributed by: